Skip to content

REATA PHARMACEUTICALS INC

CIK 0001358762

← back to feed
Revenue (TTM)
$24.24M
−80.7% YoY Q2 Jun 2023
Net Income (TTM)
−$75.68M
−4.9% YoY Q2 Jun 2023
EPS Diluted (TTM)
−$2.67
−4.3% YoY Q2 Jun 2023
Gross Margin
—
Q2 Jun 2023
Operating Margin
—
Q2 Jun 2023
Net Margin
-312.2%
Q2 Jun 2023
Free Cash Flow (TTM)
−$226.53M
Q2 Jun 2023
Cash
$48.84M
Q2 Jun 2023
Total Debt
$5.31M
Q2 Jun 2023
Shares Outstanding
—
Q2 Jun 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings